Comment on FDA backs Pfizer COVID-19 boosters for seniors, high-risk

The U.S. moved a step closer Wednesday to offering booster doses of Pfizer’s COVID-19 vaccine to senior citizens and others at high risk from the virus as the Food and Drug Administration signed off on the targeted use of the extra shots. The FDA authorized booster doses for Americans who are 65 and older, younger people with underlying health conditions and those in jobs that put them at high-risk for COVID-19.